京新药业
(002020)
| 流通市值：67.74亿 | | | 总市值：88.86亿 |
| 流通股本：6.56亿 | | | 总股本：8.61亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,060,660,180.25 | 3,998,835,219.87 | 2,925,537,429 | 1,936,552,392.84 |
| 营业收入 | 1,060,660,180.25 | 3,998,835,219.87 | 2,925,537,429 | 1,936,552,392.84 |
| 二、营业总成本 | 870,669,357.5 | 3,367,036,496.62 | 2,433,056,491.69 | 1,601,608,699.86 |
| 营业成本 | 510,338,395.36 | 1,976,488,431.24 | 1,433,573,708.29 | 958,381,949.85 |
| 税金及附加 | 10,138,702.59 | 46,745,308.14 | 30,135,494.76 | 19,937,637.51 |
| 销售费用 | 207,904,913.74 | 783,527,330.14 | 605,886,403.51 | 398,280,246.7 |
| 管理费用 | 52,083,952.53 | 213,168,211.63 | 142,240,172.72 | 86,547,683.31 |
| 研发费用 | 98,380,244.05 | 400,934,730.87 | 259,456,442.07 | 171,121,111.71 |
| 财务费用 | -8,176,850.77 | -53,827,515.4 | -38,235,729.66 | -32,659,929.22 |
| 其中:利息费用 | 3,737,540.65 | 7,314,834.56 | 6,238,304.51 | - |
| 其中:利息收入 | 11,743,911.24 | 60,269,451.18 | 41,938,787.01 | - |
| 加:公允价值变动收益 | 176,705.48 | 36,770,941.18 | 1,338,184.93 | 1,002,013.7 |
| 加:投资收益 | 1,793,438.35 | 6,440,588.27 | 6,654,764.8 | 4,501,508.4 |
| 资产处置收益 | 1,673.07 | 6,859,767.39 | 4,631,051.4 | 4,325,146.43 |
| 资产减值损失(新) | -1,934,674.71 | -21,145,432.43 | 1,480,961.2 | 3,131,992.28 |
| 信用减值损失(新) | -3,153,908.97 | -5,137,515.63 | 599,398.32 | -2,454,943.02 |
| 其他收益 | 15,179,922.22 | 58,471,887.63 | 28,303,902.97 | 19,169,229.71 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 202,053,978.19 | 714,058,959.66 | 535,489,200.93 | 364,618,640.48 |
| 加:营业外收入 | 177,638 | 2,471,375.58 | 1,901,496.08 | 1,594,407.32 |
| 减:营业外支出 | 114,336.88 | 8,489,543.29 | 1,297,613.79 | 1,226,941.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 202,117,279.31 | 708,040,791.95 | 536,093,083.22 | 364,986,105.99 |
| 减:所得税费用 | 28,905,146.7 | 84,623,219.09 | 60,140,798.91 | 46,538,933.54 |
| 六、净利润 | 173,212,132.61 | 623,417,572.86 | 475,952,284.31 | 318,447,172.45 |
| 持续经营净利润 | 173,212,132.61 | 623,608,462.8 | 475,952,284.31 | 318,447,172.45 |
| 终止经营净利润 | - | -190,889.94 | - | - |
| 归属于母公司股东的净利润 | 171,207,841.45 | 618,898,033.74 | 472,623,535.41 | 315,924,154.48 |
| 少数股东损益 | 2,004,291.16 | 4,519,539.12 | 3,328,748.9 | 2,523,017.97 |
| (一)基本每股收益 | 0.2 | 0.72 | 0.55 | 0.37 |
| (二)稀释每股收益 | 0.2 | 0.72 | 0.55 | 0.37 |
| 八、其他综合收益 | 284,399.46 | -333,762.92 | 680,903.1 | 574,986.39 |
| 归属于母公司股东的其他综合收益 | 274,282.49 | -333,902.34 | 667,605.43 | 565,024.84 |
| 九、综合收益总额 | 173,496,532.07 | 623,083,809.94 | 476,633,187.41 | 319,022,158.84 |
| 归属于母公司股东的综合收益总额 | 171,482,123.94 | 618,564,131.4 | 473,291,140.84 | 316,489,179.32 |
| 归属于少数股东的综合收益总额 | 2,014,408.13 | 4,519,678.54 | 3,342,046.57 | 2,532,979.52 |
| 公告日期 | 2024-04-24 | 2024-03-30 | 2023-10-27 | 2023-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |